HEALTHSEMAFOR
$35 insulin deal has 60 votes in Senate
A bipartisan Senate deal to cap insulin prices at $35 for Americans with employer-sponsored or private insurance has secured 60 votes, including support from 47 Democrats and 13 Republicans. Public polling indicates 68% support for the measure, with potential political benefits for both parties.
Mentioned
Related Signal
Adjacent reporting
- Insulin legislation gains steam
- Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiative
- STAT+: Maryland state affordability board places a price cap on Ozempic
- Three GOP senators back Sanders amendment to slash drug prices
- Health costs outweigh food, vaccine concerns for MAHA voters: Poll
- Trump cuts drug price deal with Regeneron